Bristol Myers Squibb Company $BMY Stock: Cibc World Market Inc. Increases Stake

Cibc World Market Inc. raised its holdings in Bristol Myers Squibb Company (NYSE:BMY – Free Report) by 55.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 635,279 shares of the biopharmaceutical company’s stock after buying an additional 225,851 shares during the quarter. Cibc World Market Inc.’s holdings in Bristol Myers Squibb were worth $39,641,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. grew its stake in shares of Bristol Myers Squibb by 5.1% in the second quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company’s stock worth $10,393,783,000 after acquiring an additional 8,702,106 shares during the last quarter. State Street Corp increased its position in Bristol Myers Squibb by 7.3% during the second quarter. State Street Corp now owns 105,757,638 shares of the biopharmaceutical company’s stock worth $6,093,755,000 after acquiring an additional 7,192,724 shares during the period. Primecap Management Co. CA bought a new position in Bristol Myers Squibb during the second quarter worth $1,436,115,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in Bristol Myers Squibb by 0.5% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 22,839,010 shares of the biopharmaceutical company’s stock worth $1,315,984,000 after acquiring an additional 119,690 shares during the period. Finally, Legal & General Group Plc acquired a new position in Bristol Myers Squibb during the 2nd quarter valued at $980,862,000. 76.41% of the stock is owned by institutional investors.

Bristol Myers Squibb Stock Performance

BMY opened at $59.49 on Thursday. The stock’s 50 day simple moving average is $61.65 and its 200-day simple moving average is $60.41. The company has a current ratio of 1.59, a quick ratio of 1.44 and a debt-to-equity ratio of 1.79. The stock has a market cap of $121.61 billion, a PE ratio of 13.19, a P/E/G ratio of 0.32 and a beta of 0.20. Bristol Myers Squibb Company has a 1 year low of $45.26 and a 1 year high of $68.64.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last issued its earnings results on Thursday, October 29th. The biopharmaceutical company reported $1.35 EPS for the quarter, topping the consensus estimate of $1.10 by $0.25. Bristol Myers Squibb had a return on equity of 60.48% and a net margin of 18.47%. The firm had revenue of $13.07 billion during the quarter, compared to analysts’ expectations of $12.72 billion. During the same period last year, the business earned $1.63 earnings per share. Bristol Myers Squibb’s quarterly revenue was up 6.9% compared to the same quarter last year. Sell-side analysts forecast that Bristol Myers Squibb Company will post 6.46 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, November 2nd. Stockholders of record on Friday, October 2nd were paid a $0.63 dividend. The ex-dividend date was Friday, October 2nd. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio is currently 55.88%.

Key Bristol Myers Squibb News

Investors following BMY have been watching these news items:

Analyst Ratings Changes

BMY has been the subject of a number of research reports. William Blair reissued a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, October 12th. Weiss Ratings restated a “buy (b-)” rating on shares of Bristol Myers Squibb in a report on Monday. Bank of America restated a “buy” rating on shares of Bristol Myers Squibb in a report on Friday, October 30th. Daiwa Securities Group upped their price objective on shares of Bristol Myers Squibb from $53.00 to $66.00 and gave the company a “neutral” rating in a research report on Tuesday, August 4th. Finally, Morgan Stanley reduced their target price on shares of Bristol Myers Squibb from $41.00 to $40.00 and set an “underweight” rating for the company in a research note on Friday, October 30th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, sixteen have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $65.46.

Read Our Latest Report on BMY

Insiders Place Their Bets

In other news, Director Julia Haller sold 3,800 shares of the firm’s stock in a transaction dated Thursday, November 5th. The shares were sold at an average price of $63.31, for a total transaction of $240,578.00. Following the completion of the transaction, the director directly owned 30,279 shares of the company’s stock, valued at approximately $1,916,963.49. This trade represents a 11.15% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Phil M. Holzer sold 500 shares of Bristol Myers Squibb stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the sale, the senior vice president owned 16,862 shares in the company, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Corporate insiders own 0.05% of the company’s stock.

Bristol Myers Squibb Company Profile

(Free Report)

Bristol Myers Squibb is a global biopharmaceutical company that discovers, develops, manufactures and markets medicines. Its research and commercial activities focus on serious diseases, particularly cancer, blood disorders, immune-mediated conditions and cardiovascular disease. The company’s medicines include Opdivo and Yervoy for cancer, Eliquis for preventing and treating blood clots, and Orencia for certain autoimmune conditions. Its portfolio also includes treatments for hematologic diseases and other serious illnesses.

Recommended Stories

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY – Free Report).

Institutional Ownership by Quarter for Bristol Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.